ChinaDaily Briefs

China: China Conch Venture Holdings, TK Group (Holdings), Shanghai Microport Endovascular MedTech, Ashtead Group PLC, Road King Infrastructure and more

In today’s briefing:

  • Conch Venture (586 HK): Another Spin-Off in the Pipeline
  • Investing in HK Stocks
  • Shanghai Microport Endovascular MedTech (688016.CH) 21/22Q1 – This Is a Company Worth Investing In
  • Aristotle Capital Management International Equity ADR 1Q 2022 Commentary
  • Morning Views Asia: Japfa Comfeed Indonesia, Melco Resorts & Entertainment

Conch Venture (586 HK): Another Spin-Off in the Pipeline

By Osbert Tang, CFA

  • Following listing of China Conch Environment (587 HK), China Conch Venture (586 HK) is seeking a spin-off of CV Green Energy in A-share market and we view this move positively.
  • Limited details are currently available, but we think CV Green Energy, which operates WTE businesses, will trade at significantly higher multiples than its Hong Kong peers. 
  • Assuming CV Green Energy to hold all Conch Venture’s WTE businesses, we estimate the IPO will boost the latter’s sum-of-the-parts value by 8% or HK$2.14 per share.

Investing in HK Stocks

By Turtles all the way down

  • I think most (value) investors go through four stages: Stage 0: Buy stuff that goes up. Especially when a lot of people around you get rich from doing it.
  • Stage 1: Invest in the future! Buy into some fancy exciting new technology that will become big some day! The Cathie Wood stage. Usually stage 1 and stage 0 go hand in hand.
  • Stage 2: Buy at low PE multiples. Some are smart and skip the first two. This stage is not bad, it should lead to slight outperformance. Can be dangerous without wide diversification as a lot of them are value traps.

Shanghai Microport Endovascular MedTech (688016.CH) 21/22Q1 – This Is a Company Worth Investing In

By Xinyao (Criss) Wang

  • The aortic product line would bring strong growth in 1-2 years. From 3 years or longer term, Endovascular’s peripheral vascular interventional devices would be the main driver for high growth.
  • We don’t think the centralized procurement would be a concern for the time being. As many products are or will apply for CE Mark, the progress of internationalization is promising.
  • The current valuation is very attractive. Due to the pandemic/lockdown in China and many external uncertainties, share price could go lower, but it’s still a good company to invest in.

Aristotle Capital Management International Equity ADR 1Q 2022 Commentary

By Fund Newsletters

  • For Q1 2022, Aristotle Capital’s International Equity ADR Composite posted a total USD return of -9.75% gross of fees.
  • The company is an independent/employee-owned investment management organization that specializes in equity and fixed income portfolio management for institutional and advisory clients worldwide.

Morning Views Asia: Japfa Comfeed Indonesia, Melco Resorts & Entertainment

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Before it’s here, it’s on Smartkarma